Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.


Priority Review Granted for Nab-Paclitaxel in Metastatic Pancreatic Cancer

May 23rd 2013

The FDA has granted priority review to nab-paclitaxel in combination with gemcitabine for the first-line treatment of patients with metastatic pancreatic cancer.

Chip Petricoin on the Discovery of New Biomarkers

May 20th 2013

Emanuel F. "Chip" Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses the discovery of new biomarkers in breast cancer.

Dr. Karsh Discusses Treatment Sequencing in mCRPC

May 17th 2013

Lawrence Karsh, MD, from The Urology Center of Colorado, discusses strategies for sequencing treatments for men with metastatic castration-resistant prostate cancer.

Is Our Healthcare System Ready to Integrate Cancer Care?

May 16th 2013

In response to the billions of dollars wasted each year in the United States on fragmented, ineffective, and uncoordinated care, some healthcare reform efforts have focused on integrating the delivery of healthcare.

Sledge Expects "Big Data" to Generate Big Changes

May 15th 2013

The technological advances in analyzing the human genome have spawned a new era in breast cancer as well as other types of malignancies that will affect oncology practice and will necessitate dramatic changes in the clinical trials system.

Radium-223 Approved For Advanced Prostate Cancer

May 15th 2013

The FDA approved radium RA 223 dichloride for the treatment of symptomatic metastatic castration-resistant prostate cancer that has spread to the bones but not to any other organs.

FDA Approves Frontline Erlotinib With Novel Companion Diagnostic for Advanced NSCLC

May 14th 2013

The FDA concurrently approved erlotinib along with a companion diagnostic to be used together in the first-line treatment of patients with metastatic non-small cell lung cancer harboring a specific EGFR mutation.

Value-Based Purchasing: How Physicians Will Be Compensated in the Future

May 10th 2013

An interview with Frank G. Opelka, MD, exploring some of the health policy initiatives that will impact how physicians will be compensated in the future.

Integrating New Therapies Into the Prostate Cancer Continuum

May 9th 2013

Several case studies highlighting the latest strategies and therapeutic agents available for patients with prostate cancer.

Herbert Irving Comprehensive Cancer Center Joins OncLive's Strategic Alliance Partnership

May 7th 2013

OncLive is pleased to announce that the Herbert Irving Comprehensive Cancer Center has joined its Strategic Alliance Partnership program. This program enables the Herbert Irving Comprehensive Cancer Center to promote its institution and faculty as leaders in oncology to a national audience of oncology professionals.

AUA Offers Evidence-Based Guide For Sequencing CRPC Therapies

May 6th 2013

The American Urological Association outlines clinical guidelines for sequencing castration-resistant prostate cancer therapies based on six "index patients" each with specific disease characteristics.

ODAC Turns Down Chemosaturation System

May 2nd 2013

Citing concerns about the safety profile of the device, ODAC unanimously recommended against the approval of the Melblez chemosaturation system for use with melphalan hydrochloride in the treatment of patients with ocular melanoma metastasized to the liver.

ODAC Votes Against Tivozanib in Renal Cell Carcinoma

May 2nd 2013

A single clinical trial was deemed insufficient to support approval of tivozanib for the treatment of patients with advanced renal cell carcinoma, according to a 13-1 vote by the FDA's Oncologic Drugs Advisory Committee.

Surveillance Following Orchiectomy Most Costly Option for Stage I Testicular Seminoma

May 2nd 2013

A cost analysis found that para-aortic radiotherapy, dogleg radiotherapy, and 1 cycle of carboplatin are cost-effective strategies for the management of stage I testicular seminoma post-orchiectomy compared with surveillance.

Breakthrough Designation Granted to Daratumumab for Double Refractory Multiple Myeloma

May 1st 2013

An investigational monoclonal antibody called daratumumab has received breakthrough therapy designation from the FDA for the treatment of patients with double refractory multiple myeloma.

PD-1 Targeted Antibody Lambrolizumab Receives FDA Breakthrough Designation

April 25th 2013

Lambrolizumab, an investigational antibody designed to target the programmed death-1 (PD-1) pathway in patients with melanoma, received a breakthrough therapy designation from the FDA after promising results from a small single-arm study.

Dr. Richard Silver Discusses the High Cost of Drugs in CML

April 24th 2013

Richard T. Silver, MD, from the New York Presbyterian-Weill Cornell Medical Center, comments on the cost of drugs to treat chronic myeloid leukemia.

Focusing on Clinical and Economic Outcomes-Not Guidelines: Is It Time for a New Direction in Oncology Care?

April 24th 2013

Interview With Andrew Pecora, MD, President, Regional Cancer Care Associates, Chief Innovations Officer and Vice President, Cancer Services, John Theurer Cancer Center at Hackensack University Medical Center, Editor-in-Chief, Oncology & Biotech News

April 2013 Biotech Focus: Tracking the Oncology Pipeline

April 19th 2013

The Biotech Focus series provides updates on advances in the oncology treatment pipeline. In each entry, summaries of ongoing research, breaking news, and FDA decisions relating to a variety of cancers are presented.

Emanuel Petricoin Describes Screening With Biomarkers

April 16th 2013

Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses disease screening with biomarkers.

NEXT PAGE
PREVIOUS PAGE